AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
molsidomine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1831 | 25717-80-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 52 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.40 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 11 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAPK7,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PRKDC,SIK2,SIK3,STK33,TEK,TTK | 33 | |||
| kinase-selectivity-class | AXL,BRAF,DDR1,EPHB4,GRK2,MAPK7,PRKDC,STK33,TEK,TTK | 10 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 219.54 | 52.34 | 63 | 1971 | 32465 | 90593948 |
| Mucosal erosion | 109.96 | 52.34 | 21 | 2013 | 1824 | 90624589 |
| Antinuclear antibody negative | 109.21 | 52.34 | 16 | 2018 | 270 | 90626143 |
| Coombs positive haemolytic anaemia | 100.60 | 52.34 | 16 | 2018 | 474 | 90625939 |
| Antiphospholipid syndrome | 93.61 | 52.34 | 19 | 2015 | 2255 | 90624158 |
| Dermatitis exfoliative | 92.13 | 52.34 | 22 | 2012 | 5514 | 90620899 |
| Herpes simplex reactivation | 82.37 | 52.34 | 15 | 2019 | 1004 | 90625409 |
| Gastritis haemorrhagic | 79.81 | 52.34 | 16 | 2018 | 1784 | 90624629 |
| Cholecystitis | 75.86 | 52.34 | 24 | 2010 | 17016 | 90609397 |
| Hyperthyroidism | 74.17 | 52.34 | 24 | 2010 | 18286 | 90608127 |
| Complex regional pain syndrome | 73.59 | 52.34 | 16 | 2018 | 2643 | 90623770 |
| Electrolyte imbalance | 68.05 | 52.34 | 24 | 2010 | 23721 | 90602692 |
| Conjunctivitis | 65.29 | 52.34 | 24 | 2010 | 26682 | 90599731 |
| Anxiety disorder | 63.78 | 52.34 | 16 | 2018 | 4906 | 90621507 |
| Respiratory disorder | 59.43 | 52.34 | 29 | 2005 | 64787 | 90561626 |
| Genital erosion | 58.73 | 52.34 | 10 | 2024 | 453 | 90625960 |
| Erysipelas | 58.53 | 52.34 | 17 | 2017 | 9035 | 90617378 |
| Multiple organ dysfunction syndrome | 57.97 | 52.34 | 29 | 2005 | 68307 | 90558106 |
| Fall | 55.98 | 52.34 | 61 | 1973 | 481749 | 90144664 |
| Product prescribing error | 55.39 | 52.34 | 22 | 2012 | 30123 | 90596290 |
| Erythema | 53.80 | 52.34 | 43 | 1991 | 229203 | 90397210 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| General physical health deterioration | 62.63 | 34.73 | 49 | 1560 | 151197 | 42468529 |
| Oral mucosal eruption | 54.83 | 34.73 | 10 | 1599 | 397 | 42619329 |
| Pyelitis | 42.50 | 34.73 | 7 | 1602 | 151 | 42619575 |
| Syncope | 36.33 | 34.73 | 30 | 1579 | 99376 | 42520350 |
| Orthostatic intolerance | 35.90 | 34.73 | 8 | 1601 | 875 | 42618851 |
| Dizziness | 35.23 | 34.73 | 45 | 1564 | 249209 | 42370517 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 164.05 | 33.68 | 62 | 3208 | 56665 | 110529364 |
| Mucosal erosion | 95.23 | 33.68 | 21 | 3249 | 2803 | 110583226 |
| Product prescribing error | 86.10 | 33.68 | 38 | 3232 | 51293 | 110534736 |
| Electrolyte imbalance | 70.54 | 33.68 | 30 | 3240 | 36998 | 110549031 |
| Dermatitis exfoliative | 70.44 | 33.68 | 22 | 3248 | 11325 | 110574704 |
| Hyperthyroidism | 56.70 | 33.68 | 24 | 3246 | 29237 | 110556792 |
| Cholecystitis | 56.11 | 33.68 | 23 | 3247 | 25859 | 110560170 |
| Conjunctivitis | 53.37 | 33.68 | 24 | 3246 | 33768 | 110552261 |
| Genital erosion | 50.37 | 33.68 | 10 | 3260 | 801 | 110585228 |
| Respiratory disorder | 49.21 | 33.68 | 29 | 3241 | 71353 | 110514676 |
| Fall | 46.74 | 33.68 | 72 | 3198 | 603410 | 109982619 |
| Oral mucosal eruption | 46.66 | 33.68 | 10 | 3260 | 1167 | 110584862 |
| General physical health deterioration | 45.11 | 33.68 | 59 | 3211 | 425236 | 110160793 |
| Antinuclear antibody negative | 44.42 | 33.68 | 7 | 3263 | 146 | 110585883 |
| Blister | 43.72 | 33.68 | 43 | 3227 | 227333 | 110358696 |
| Stevens-Johnson syndrome | 43.05 | 33.68 | 23 | 3247 | 46878 | 110539151 |
| Antiphospholipid syndrome | 39.07 | 33.68 | 10 | 3260 | 2513 | 110583516 |
| Syncope | 38.36 | 33.68 | 38 | 3232 | 202498 | 110383531 |
| Erythema | 38.20 | 33.68 | 45 | 3225 | 291402 | 110294627 |
| Purpura | 37.48 | 33.68 | 17 | 3253 | 24371 | 110561658 |
| Pyelitis | 37.23 | 33.68 | 7 | 3263 | 421 | 110585608 |
| Cholelithiasis | 36.60 | 33.68 | 23 | 3247 | 63399 | 110522630 |
FDA Adverse Event Reporting System (Pediatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Small for dates baby | 16.84 | 16.83 | 7 | 4 | 3733 | 110209 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01DX12 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY VASODILATORS USED IN CARDIAC DISEASES Other vasodilators used in cardiac diseases |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D020030 | Nitric Oxide Donors |
| CHEBI has role | CHEBI:22586 | antioxidant |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:50566 | nitric oxide donor |
| CHEBI has role | CHEBI:68494 | apoptosis inhibitor |
| CHEBI has role | CHEBI:77307 | cardioprotective agent |
Related Drugs by ATC class:
C01DX Other vasodilators used in cardiac diseases 18 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Angina pectoris | indication | 194828000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.48 | acidic |
| pKa2 | 6.72 | Basic |
| pKa3 | 1.29 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | IC50 | 4.61 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000167103 | NUI |
| D01320 | KEGG_DRUG |
| C0026400 | UMLSCUI |
| CHEBI:31861 | CHEBI |
| CHEMBL1329455 | ChEMBL_ID |
| DB09282 | DRUGBANK_ID |
| D008981 | MESH_DESCRIPTOR_UI |
| 5353788 | PUBCHEM_CID |
| 3125 | INN_ID |
| D46583G77X | UNII |
| 7023 | RXNORM |
| 005842 | NDDF |
| 698196008 | SNOMEDCT_US |
| D46583G77X | INXIGHT DRUGS |
Pharmaceutical products:
None